NHS directed to boost hep C testing, but guidance falls short of concerns
This article was originally published in Clinica
The UK's chief medical and chief nursing officers have written to all NHS primary care trusts (PCTs), urging them to improve the rates of detection and diagnosis of hepatitis C, with a focus on pre-emptive and confirmatory testing. The move will go some way to assuaging the Hepatitis C Trust (HCT), the UK's leading lobby and patient support group, but falls short of fully meeting its concerns, as submitted to the health select committee (HSC) for its recently-launched inquiry into patient safety*.
You may also be interested in...
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.